For years, some med spas treated the medical director role like a checkbox. A physician’s name appeared on the website, the agreement sat in a file, and the business moved forward as if that alone were enough.
In 2026, that approach looks much riskier.
Across multiple states, the direction of regulation is becoming clearer: regulators want active medical director involvement, not a distant physician who has little real connection to the clinic. Rhode Island now requires documented supervision arrangements, written competency expectations, and formal licensing under the Department of Health. Indiana has moved to a registration model that requires each med spa to designate a qualified responsible practitioner with prescriptive authority, appropriate training, and oversight responsibility for staff and compounded drug use. Texas has already tightened the rules around elective IV therapy by requiring meaningful physician oversight, written protocols, and real delegation standards. Florida, while still pending as of March 2026, is moving in the same direction with a proposal that would require a licensed responsible person with supervising authority and physical presence sufficient to ensure compliance.      Â
That shift is what makes the idea of the “ghost director” so dangerous now.
What a “Ghost Director” Really Means
A ghost director is not a formal legal term. It is the practical label many people use for a physician whose involvement is mostly nominal. Their name may be attached to the clinic, but their actual oversight is weak, inconsistent, or functionally absent.
That kind of arrangement becomes hard to defend when a state starts asking basic questions. Who is supervising the people performing treatments? Who reviewed the protocols? Who is responsible for training, delegation, adverse event response, and patient-facing medical decisions? If the answer is vague, the clinic has a structural problem, not just a paperwork problem.
The states highlighted here are all pointing toward the same expectation: medical oversight has to be real.
Rhode Island Is Demanding Documented Supervision
Rhode Island’s Medical Aesthetic Practices Safety Act took effect on January 1, 2026, and it is one of the clearest examples of this trend. The law classifies medical spas as licensed healthcare facilities under the Rhode Island Department of Health and requires provider qualifications, written supervision agreements, documented competency, and written informed consent with provider identity and licensure disclosure. RIDOH also has broad authority to investigate and discipline non-compliant clinics.  Â
That matters because a ghost-director model does not fit comfortably inside a system built on documented supervision and regulatory oversight. If supervision agreements must be in writing and maintained on file, and if staff competency must be demonstrated for specific procedures, the physician relationship can no longer exist as a loose affiliation.Â
In practical terms, Rhode Island is pushing med spas toward visible, defensible clinical leadership.
Indiana Is Focusing on Accountable Oversight
Indiana’s SB 282 moves in a slightly different direction, but the message is similar. The law requires med spas to register with the Indiana Medical Licensing Board by January 1, 2027, and each location must designate a responsible practitioner. That person must have prescriptive authority, appropriate education and training in the services and medications used at the med spa, and responsibility for making sure staff are licensed and properly trained. The same law also places oversight responsibility for compounded drug use on that responsible practitioner and allows board inspections of registered facilities.  Â
This is exactly the kind of framework that exposes nominal oversight. A clinic cannot realistically claim to have a responsible practitioner if no one is actively checking staff qualifications, supervising treatment-related workflows, or taking responsibility for compounded medications and adverse event reporting. Indiana also requires serious adverse events to be reported within five days, which further reinforces that someone must be meaningfully engaged in the operation.Â
The title may be different from “medical director,” but the principle is the same: accountability has to attach to a real person with real involvement.
Texas is Rejecting Distant, Uninvolved Oversight
Texas already offers one of the clearest warnings against ghost-director arrangements. Under HB 3749, which is in effect for 2026 operations, elective IV therapy must be delegated by a physician under proper oversight, and written delegation protocols must be maintained. The law and related rule updates also require adequate supervision, Good Faith Exams for applicable delegation, BLS-trained personnel on site during elective IV therapy, and patient transparency about who is providing treatment and how oversight works. The document is especially direct in stating that medical directors may not be “100+ miles away and uninvolved” and that meaningful oversight is required.  Â
That language is a problem for any clinic still relying on a physician who is present only on paper.
Texas does not say every med spa service now requires the exact same IV-therapy framework, and the law is specifically aimed at elective IV therapy rather than all cosmetic injection services. But the broader compliance lesson is still important: when the state starts spelling out active delegation, supervision, protocols, and transparency, nominal medical direction becomes much harder to justify.  Â
Clinics that rely on medical director services in Texas need real physician involvement behind the role, not just paperwork.
Florida Is Not Law Yet, But the Direction Is Obvious
Florida is different because the 2026 Medical Spa Prescription Drug Oversight Act is still pending as of March 2026. It has not been enacted. Still, the proposal is worth watching because it points in the same regulatory direction. If passed, med spas handling prescription medications would need a Board of Pharmacy license, and each licensed location would have to designate a responsible person defined as a licensed healthcare provider with supervising authority. That person would need to be physically present for a sufficient amount of time to ensure compliance and would be accountable for the security and control of prescription drugs at the facility.  Â
Even though Florida’s bill is not yet in effect, it reflects a broader policy trend: oversight is being tied to actual presence, accountability, and medication control, not just affiliation.
For Florida operators, that makes Florida medical director services less of a branding question and more of a readiness question.
What Med Spas Should Take From This Trend
The common thread across these states is not just stricter regulation. It has stricter expectations about involvement.
Regulators are looking for things like written supervision agreements, qualified responsible practitioners, meaningful delegation, documented protocols, adverse event response, and enough real physician presence to support compliance. Rhode Island and Indiana have already enacted major changes. Texas has already tightened oversight in a targeted but meaningful area. Florida may be next if its pending bill passes.      Â
That is bad news for ghost-director models and good news for clinics that want to build something defensible.
The safest interpretation of 2026 is this: a medical director should be clinically engaged, operationally present where needed, and clearly responsible for oversight in a way the clinic can document.
The Wellness MD Group Director Difference
This is where the right medical director structure matters. Clinics do not need a name on a wall. They need a physician relationship that can stand up to real-world scrutiny.
New state frameworks are moving toward meaningful involvement, responsible practitioners, written supervision, and active oversight. Clinics that build around genuinely involved medical leadership will be in a much stronger position than clinics still relying on nominal physician arrangements.      Â
That is the real takeaway from the 2026 crackdown: regulators are paying less attention to titles and more attention to whether the medical director is actually doing the job.
